ATE307119T1 - Bicyclische protein-farnesyl-transferase inhibitoren - Google Patents
Bicyclische protein-farnesyl-transferase inhibitorenInfo
- Publication number
- ATE307119T1 ATE307119T1 AT98906491T AT98906491T ATE307119T1 AT E307119 T1 ATE307119 T1 AT E307119T1 AT 98906491 T AT98906491 T AT 98906491T AT 98906491 T AT98906491 T AT 98906491T AT E307119 T1 ATE307119 T1 AT E307119T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- transferase inhibitors
- farnesyl transferase
- present
- protein farnesyl
- Prior art date
Links
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3750497P | 1997-02-11 | 1997-02-11 | |
| PCT/US1998/003025 WO1998034921A1 (en) | 1997-02-11 | 1998-02-11 | Bicyclic inhibitors of protein farnesyl transferase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE307119T1 true ATE307119T1 (de) | 2005-11-15 |
Family
ID=21894697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98906491T ATE307119T1 (de) | 1997-02-11 | 1998-02-11 | Bicyclische protein-farnesyl-transferase inhibitoren |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US6133303A (de) |
| EP (1) | EP0966446B1 (de) |
| JP (1) | JP2001518076A (de) |
| KR (1) | KR20000070924A (de) |
| AT (1) | ATE307119T1 (de) |
| AU (1) | AU725696B2 (de) |
| BR (1) | BR9807674A (de) |
| CA (1) | CA2273895A1 (de) |
| DE (1) | DE69831937T2 (de) |
| ES (1) | ES2252827T3 (de) |
| NZ (1) | NZ336134A (de) |
| WO (1) | WO1998034921A1 (de) |
| ZA (1) | ZA981080B (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2477400A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO2000034239A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| EP1276725A2 (de) * | 2000-04-17 | 2003-01-22 | Warner-Lambert Company | 5-substituierte tetralonen als ras farnesyl inhibitoren |
| AU2001251649A1 (en) * | 2000-04-17 | 2001-10-30 | Warner Lambert Company | Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| JP4596916B2 (ja) * | 2002-09-05 | 2010-12-15 | メディミューン，エルエルシー | Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法 |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| KR101224235B1 (ko) | 2003-04-11 | 2013-01-25 | 메디뮨 엘엘씨 | 재조합 ｉｌ９ 항체 및 그의 용도 |
| EP1660186B1 (de) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanisierung von antikörpern |
| US7550482B2 (en) * | 2004-02-27 | 2009-06-23 | Merz Pharma Gmbh & Co. Kgaa | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors |
| US20060004001A1 (en) * | 2004-02-27 | 2006-01-05 | Merz Pharma Gmbh & Co., Kgaa | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors |
| WO2006047639A2 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| EP1869192B1 (de) | 2005-03-18 | 2016-01-20 | MedImmune, LLC | Rahmenmischung von antikörpern |
| KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
| WO2007041697A2 (en) * | 2005-10-04 | 2007-04-12 | Medivation, Inc. | Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease |
| EP2484696B1 (de) | 2006-08-28 | 2017-08-16 | Kyowa Hakko Kirin Co., Ltd. | Antagonistische hLIGHT-spezifische menschliche monoklonale Antikörper |
| KR101540823B1 (ko) | 2007-03-30 | 2015-07-30 | 메디뮨 엘엘씨 | 항체 제제 |
| EP2215246B1 (de) | 2007-10-31 | 2015-01-07 | MedImmune, LLC | Proteingerüste |
| MX2011000355A (es) * | 2008-07-10 | 2011-04-07 | Southern Res Inst | Compuestos de 5-quinolinona e imidazopirimidina y utilizacion de los mismos. |
| US8725967B2 (en) * | 2008-08-08 | 2014-05-13 | Amazon Technologies, Inc. | Providing executing programs with access to stored block data of others |
| US20120189633A1 (en) | 2011-01-26 | 2012-07-26 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
| EP4063391A1 (de) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit-antikörper und verwendungen davon |
| SG11201502757QA (en) | 2012-10-09 | 2015-05-28 | Igenica Biotherapeutics Inc | Anti-c16orf54 antibodies and methods of use thereof |
| EP3003390B1 (de) | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anti-c10orf54-antikörper und verwendungen davon |
| CN105764526B (zh) | 2013-08-26 | 2020-12-15 | 生物技术研发公司 | 编码抗唾液酸化路易斯a抗原的人抗体的核酸 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9856324B2 (en) | 2014-06-04 | 2018-01-02 | MabVax Therapeutics, Inc. | Human monoclonal antibodies to ganglioside GD2 |
| KR102693806B1 (ko) | 2014-12-11 | 2024-08-09 | 피에르 파브르 메디카먼트 | 항-c10orf54 항체들 및 그들의 용도들 |
| PL3265123T3 (pl) | 2015-03-03 | 2023-03-13 | Kymab Limited | Przeciwciała, zastosowania i sposoby |
| JP7227007B2 (ja) | 2015-12-02 | 2023-02-21 | ストサイエンシス， インコーポレイテッド | グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体 |
| KR102803158B1 (ko) | 2015-12-02 | 2025-05-08 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도 |
| CN105801421A (zh) * | 2016-03-31 | 2016-07-27 | 常州大学 | 一种2-醛基-3-羟基-4,6-二氯苯甲酸的合成方法 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN111148762A (zh) | 2017-05-31 | 2020-05-12 | 斯特库伯株式会社 | 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途 |
| CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| JP2020522562A (ja) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー．， インコーポレイテッド | Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法 |
| US11707522B2 (en) | 2017-10-13 | 2023-07-25 | Boehringer Ingelheim International Gmbh | Human antibodies to Tn antigen |
| KR20250024129A (ko) | 2018-07-20 | 2025-02-18 | 피에르 파브르 메디카먼트 | Vista의 수용체 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535225A (de) * | 1969-03-29 | 1973-03-31 | Schering Ag | Verfahren zur Herstellung von heterocyclischen Nitroverbindungen |
| DE1937630A1 (de) * | 1969-07-19 | 1971-02-04 | Schering Ag | 2-(5-Nitro-2-furfuryliden)-l-tetralone |
| JPS6013788A (ja) * | 1983-07-05 | 1985-01-24 | Yamanouchi Pharmaceut Co Ltd | 新規なクマリン誘導体 |
| BR8305086A (pt) | 1983-09-19 | 1984-03-20 | Antonio Signori | Dispositivo de amortecimento aplicavel a calcados em geral |
| ES8601148A1 (es) * | 1984-12-10 | 1985-11-16 | Ferrer Int | Procedimiento de obtencion de nuevos derivados imidazoliletoxiindanicos. |
| MX13485A (es) * | 1987-10-19 | 1993-05-01 | Pfizer | Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos |
| US5059609A (en) * | 1987-10-19 | 1991-10-22 | Pfizer Inc. | Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases |
| GB2244431A (en) * | 1990-05-31 | 1991-12-04 | Farmos Oy | Treatment of age related memory impairment and other cognitive disorders |
| US5149703A (en) * | 1991-09-06 | 1992-09-22 | Merck Frosst Canada, Inc. | Quinoline-substituted chromans and related compounds as leukotriene antagonists |
| USRE37303E1 (en) * | 1992-01-10 | 2001-07-31 | Institut National Del La Sante Et De La Recherche Medicale | Imidazole compounds and their therapeutic applications |
| US5641789A (en) * | 1992-10-21 | 1997-06-24 | Pfizer Inc. | Sulfonamide derivatives of benzenefused hydroxy substituted cycloalkyl and heterocyclic ring compounds |
| US6075037A (en) * | 1994-06-09 | 2000-06-13 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| EP0695753A1 (de) * | 1994-08-05 | 1996-02-07 | Zeneca Limited | Carbapenem-Derivate mit einem bicyclischen Substituenten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| ATE236632T1 (de) * | 1995-11-06 | 2003-04-15 | Univ Pittsburgh | Inhibitoren der protein-isoprenyl-transferase |
| US6090948A (en) * | 1996-01-30 | 2000-07-18 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0891335A4 (de) * | 1996-04-03 | 2001-08-16 | Merck & Co Inc | Inhibitoren von farnesylprotein-transferase |
| US5977134A (en) * | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6127390A (en) * | 1997-10-02 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6410539B1 (en) * | 1997-10-22 | 2002-06-25 | Astrazenca Uk Limited | Imidazole derivatives and their use as farnesyl protein transferase inhibitors |
| FR2787451B1 (fr) * | 1998-12-18 | 2001-01-26 | Adir | Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6143766A (en) * | 1999-04-16 | 2000-11-07 | Warner-Lambert Company | Benzopyranone and quinolone inhibitors of ras farnesyl transferase |
| US6403581B1 (en) * | 2000-01-19 | 2002-06-11 | American Cyanamid Company | Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives |
-
1998
- 1998-02-10 ZA ZA981080A patent/ZA981080B/xx unknown
- 1998-02-11 US US09/355,662 patent/US6133303A/en not_active Expired - Fee Related
- 1998-02-11 BR BR9807674-4A patent/BR9807674A/pt not_active IP Right Cessation
- 1998-02-11 AT AT98906491T patent/ATE307119T1/de not_active IP Right Cessation
- 1998-02-11 WO PCT/US1998/003025 patent/WO1998034921A1/en not_active Ceased
- 1998-02-11 NZ NZ336134A patent/NZ336134A/en unknown
- 1998-02-11 AU AU61704/98A patent/AU725696B2/en not_active Ceased
- 1998-02-11 DE DE69831937T patent/DE69831937T2/de not_active Expired - Fee Related
- 1998-02-11 JP JP53510598A patent/JP2001518076A/ja not_active Abandoned
- 1998-02-11 CA CA002273895A patent/CA2273895A1/en not_active Abandoned
- 1998-02-11 EP EP98906491A patent/EP0966446B1/de not_active Expired - Lifetime
- 1998-02-11 ES ES98906491T patent/ES2252827T3/es not_active Expired - Lifetime
- 1998-02-11 KR KR1019997007189A patent/KR20000070924A/ko not_active Ceased
-
2000
- 2000-04-28 US US09/560,606 patent/US6265422B1/en not_active Expired - Fee Related
-
2001
- 2001-07-23 US US09/910,967 patent/US6528535B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0966446A1 (de) | 1999-12-29 |
| ES2252827T3 (es) | 2006-05-16 |
| AU725696B2 (en) | 2000-10-19 |
| US6133303A (en) | 2000-10-17 |
| JP2001518076A (ja) | 2001-10-09 |
| AU6170498A (en) | 1998-08-26 |
| US6528535B2 (en) | 2003-03-04 |
| WO1998034921A1 (en) | 1998-08-13 |
| US6265422B1 (en) | 2001-07-24 |
| EP0966446B1 (de) | 2005-10-19 |
| NZ336134A (en) | 2001-08-31 |
| KR20000070924A (ko) | 2000-11-25 |
| BR9807674A (pt) | 2000-02-15 |
| US20020006936A1 (en) | 2002-01-17 |
| DE69831937T2 (de) | 2006-07-27 |
| DE69831937D1 (de) | 2006-03-02 |
| ZA981080B (en) | 1998-08-12 |
| CA2273895A1 (en) | 1998-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9807674A (pt) | Inibidores bicìclicos da proteìna farnesil transferase | |
| DE69516866D1 (de) | Stereochemische wortmanninderivate | |
| ATE259826T1 (de) | Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase | |
| NO996578L (no) | Urokinase-inhibitorer | |
| UA29446C2 (uk) | Засіб для інгібування тромбіну | |
| FI971974A0 (fi) | Tienopyridiini- tai tienopyrimidiinijohdannaiset ja niiden käyttö | |
| MX9800411A (es) | Compuestos quimicos. | |
| KR950702180A (ko) | 류코트리엔 생합성 억제제로서의 치환된 아릴알키닐-및 헤테로아릴알키닐-N-하이드록시우레아(substituted arylalkynyl-and heteroarylalkyny-N-hydroxyurea inhibi tors of leukotriene biosynthesis)본 내용은 요부공개 건이므로 전문 내용을 수록하지 않았음 | |
| MX9707192A (es) | Compuestos triciclicos de carbamato, utiles para la inhibicion de la funcion de la proteina g y paratratamiento de enfermedades proliferativas. | |
| DE69719358D1 (de) | Substituierte dihydrobenzofurane als pde-hemmstoffe | |
| MX9602861A (es) | Mezcla estabilizante sinergistica. | |
| DE69831409D1 (de) | Chalcon-derivate mit antiproliferativer aktivität | |
| AU9066498A (en) | Substituted 6-alkylphenanthridines | |
| PL331347A1 (en) | Derivatives of n-benzene sulphonyl-l-proline | |
| MX9803730A (es) | Nuevo proceso de preparacion de derivados de fenilimidazolidina. | |
| CY2225B1 (en) | Organic compounds | |
| NO952427D0 (no) | Metode for behandling av kronisk prostatitt med 17 substituerte karbamoyl-4-aza-5 | |
| BR9906803A (pt) | Processo para tratamento de copd | |
| SE9700706D0 (sv) | Process for the preparation of benzothiazoline compounds | |
| AU2576901A (en) | Agents and methods for the treatment of proliferative diseases | |
| ES2173634T3 (es) | Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf. | |
| DE69528984D1 (de) | Hemmung der leukotrienbiosynthese mittels harnstoffderivaten | |
| ATE293605T1 (de) | Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |